Trial
NCT02192489
A Phase 2 Study With CC-220 in Skin Sarcoidosis
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Celgene
Collaborators
—
Condition
Sarcoidosis
Intervention
CC-220 0.3 mg Daily
Why stopped
Administrative
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-11-12